Besides their targeting abilities, mAbs are also known for inhibiting tumor cell proliferation or angiogenesis by binding specifically to cell surface receptors that are unique or overexpressed by tumor cells, such as EGFR [149]. This evidence concerns the gene CD177 and neoplasm.